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conducted in Europe. RESULTS: The search identified 25.135 articles, 889 titles 
were included for further screening and 409 abstracts for the article review step. 
A total of 308 abstracts did not meet the inclusion/exclusion criteria, leaving a 
pool of 101 articles for full text evaluation. Overall, 10 systematic reviews were 
identified, with 238 primary studies, 129 conducted in Europe. The sample sizes 
from the included primary studies from Europe revealed 20 to 15.343 patients 
with a mean of 514. Chronic conditions investigated were: heart failure, chronic 
obstructive pulmonary disease, diabetes, and cancer. Of the outcomes more 
frequently studied, integrated care appeared to improve quality of life and 
reduce hospitalization. But often results remained inconclusive. CONCLUSIONS: 
Providing a conclusion across the different chronic conditions is not possible. 
Therefore, only disease specific conclusions can be drawn. Our review suggests 
that integrated care might be advantageous for specified groups of patients, e.g. 
heart failure. Furthermore, it remains unclear which specific component is 
associated with the highest benefit for patients across chronic conditions.  
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OBJECTIVES: For SCD patients, inadequate care during pediatric to adult 
transition may result in increased emergency department (ED) utilization. 
Emergency department reliance (EDR: total ED visits/total ambulatory 
[outpatient+ED] visits) identifies the proportion of ED visits in relation to all 
ambulatory visits. This study aimed at investigating age-related patterns of EDR 
and associated health care costs in SCD patients. METHODS: State Medicaid data 
from Florida, New Jersey, Missouri, Iowa, and Kansas were analyzed. Patients 
with ≥2 SCD diagnoses (ICD-9 282.6x) and ≥1 blood transfusion were included. 
Quarterly rates of EDR and SCD complication-related ED visits as well as health 
care costs were evaluated. Based on published thresholds, high EDR was defined 
as >0.33. Regression analyses were used to assess risk factors for high EDR and 
calculate adjusted costs difference between patients with high versus low EDR. 
RESULTS: A total of 3208 patients were identified; mean (SD) observation period 
was 6.5 (3.2) years. Mean ED visits/quarter increased from 0.76 to 2.23 between 
age 15 and 23, reaching a peak of 2.9 at age 36. The most common SCD 
complication-related ED visits were pain, infection, and pneumonia. EDR rose 
from 0.15 to 0.29 between age 15 and 23, and remained high thereafter. Patients 
were more likely to have high EDR during the post-transition period (≥18 years 
old, odds ratio [OR]: 2.38, p<0.001) and when experiencing an SCD complication 
(OR: 4.18, p<0.001). Patients with high EDR incurred higher inpatient and ED 
costs, resulting in higher total costs (high vs. low EDR, adjusted costs difference, 
OP: -$285; IP: $3,485; ED: $120; Rx: -$91; total: $3,086, p<0.001 for all). 
CONCLUSIONS: Compared to children, SCD patients transitioning to adulthood 
relied more on ED for their care and those with high EDR incurred higher health 
care costs, highlighting the need to improve access to care for transitioning and 
adult SCD patients.  
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OBJECTIVES: Pharmacists are qualified to provide many services that are core to 
integrated care models. Expanding services to diverse patient populations will 
increase pharmacists’ value. This study describes the experience, preliminary 
outcomes and revenue model justification associated with the implementation 
of pharmacist-led care for patients with respiratory disorders. METHODS: 
Medical and billing record review was performed on patients with respiratory 
symptoms referred to the pharmacist from May 2011 to September 2012 within a 
community-based, medical home, primary care practice. Patients referred were 
those with respiratory symptoms in which the physician sought objective lung 
function data and additional support to assist in properly diagnosing and 
treating the patient. Pharmacist interventions included collection of a detailed 
pulmonary and medication history, spirometry, and on applicable patients, dis-
ease state education, medication care plans and device education, and smoking 
cessation. Outcomes described included quality and results of spirometry 
testing, pharmacist recommendations, recommendations for specialist care and 
payment for services. RESULTS: Thirty-four patients (76.5% female; mean 
age=49.6±17.6) were seen by the pharmacist and assessed by spirometry. 
Spirometry met American Thoracic Society quality measures in 82.5% of tests 
with the following results: 64.7% normal, obstruction (8.8% mild, 14.7% moderate, 
2.9% severe), and 8.8% probable restriction. Pharmacist recommendations that 
were implemented included the use of short-acting-beta-agonists (23.5%), 
corticosteroids (20.6%), anti-cholinergics (14.7%), and long-acting-beta-agonists 
(11.8%). Smoking cessation was recommended for 11.8% of patients and 44.1% 
received specialist referrals. The mean overall payment for the services provided 
at these visits was $144.43±36.34. CONCLUSIONS: Pharmacist involvement in the 
care of patients with respiratory disorders provided valuable, quality lung 
function data and care plan recommendations to physicians and education to 
patients. These preliminary results support the pharmacist expanding their role 
in the medical home by providing physician/patient care services, including 
spirometry, to patients with respiratory disorders from both a clinical and 
economic perspective.  
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OBJECTIVES: To review the literature published within the last decade related to 
drug-related problems and medication errors in Sub-Saharan Africa. This article 
provides a discussion on pharmaceutical care, with a focus on economic 
outcomes. METHODS: A search using Medline, Embase was conducted over the 
timeframe January 2002–December 2012 using key words such as: Sub-Saharan 
Africa, medication errors, economics, and pharmaceutical care. The abstract 
and/or full text of each article was reviewed. RESULTS: Twenty studies were 
identified for review. The most common problems in the pharmacy system were 
improper labeling, counterfeit drugs, lack of patient education, and inadequate 
drug distribution. The lack of electronic medical records and payment systems 
prevent the assessment of clinical cost outcomes. In a study conducted by the 
University of Benin, of 1500 pharmacists, 93% reported that they would be willing 
to participate in “any training program to enable them to practice pharma-
ceutical care.” There is a lack of pharmacists able to provide pharmaceutical care 
as defined as the direct, responsible provision of medication-related care 
designed to achieve definite outcomes. The shortage of pharmacists is due to 
few training institutions, migration, inadequate pay and poor working 
conditions. Specifically, 25% of the world’s global burden of disease is in Sub 
Saharan Africa, while this area comprises 3% of the world’s health workers. 
These factors contribute to an increase in medication errors. CONCLUSIONS: 
Sub-Saharan Africa lacks the necessary governmental regulation to ensure a 
decrease in medication errors. The government may consider streamlining their 
drug distribution system through the enforcement of regulations and the use of 
information technology in the health care delivery system. Additional studies are 
needed to examine economic outcomes. Several studies provide information on 
cost effectiveness and quality of life, but these studies are specific to the 
HIV/AIDS population.  
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OBJECTIVES: Health care fraud is a long-standing problem, accounting for $75 
billion in 2009. Congress amended the False Claims Act (FCA) in 1986 to allow qui 
tam relators (“whistleblowers”) to receive up to 30% of anti-fraud recoveries. 
Most studies investigate health care fraud involving the pharmaceutical 
industry, so it has not been possible to contextualize fraud involving health care 
sectors other than the pharmaceutical industry. Herein, we review all recently 
concluded major federal health care fraud investigations. METHODS: All cases 
involved health care corporations and federal FCA. Data were collected from 
Lexis/Nexis News (search terms: “Health care fraud”, “False Claims Act” and “Qui 
tam”), the Taxpayers against Fraud and the DOJ websites (2006-2011). Only cases 
with recoveries over $5 million (“major cases”) were included. Data were 
abstracted on allegations, financial settlements, occupations of and payments to 
qui tam relators. Cases are reported separately as qui tam- versus non-qui tam-
initiated to document whether the Congressional intent to encourage 
whistleblowing achieved its intended goal. RESULTS: Between 2006 and 2011, 123 
major qui tam health care FCA cases concluded, totaling $15.7 billion in 
recoveries (mean recovery: $128 million). Billing fraud, kickbacks, off-label 
marketing, and marketing unsafe pharmaceuticals were the most commonly 
implicated activities. Pharmaceutical manufacturers accounted for 31% of, and 
$11.3 billion (70%) in recoveries among qui tam relator cases. Also, 52 non-qui 
tam cases closed in this 5-year period, totaling $3.7 billion in recoveries (mean 
recovery: $71 million). Implicated activities included fraudulent billing, 
inappropriate financial relationships, off-label marketing, or marketing unsafe 
pharmaceuticals. CONCLUSIONS: In conclusion, federal investigations of fraud 
and abuse involving health care are increasing in both depth and breadth,  
and qui tam relators have an important role in detecting important fraud and 
abuse.  
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OBJECTIVES: The Patient Protection and Affordable Care Act will expand the 
eligibility of the Medicaid program to millions of Americans in 2014. Utilizing 
more generic drugs and setting appropriate pharmacy reimbursement rates 
could result in substantial savings to the Medicaid program. This study assessed 
2011 state-level, fee-for-service Medicaid generic and brand drug utilization and 
expenditures, and pharmacy reimbursement rates. METHODS: Medicaid fee-for-
service outpatient pharmacy utilization and expenditures, and reimbursement 
rates (ingredient cost and dispensing fees) for the year 2011 were extracted from 
state-level data provided from the Centers for Medicare and Medicaid Services. 
Descriptive analyses were performed for all variables in the data set. Linear 
regression analysis was performed to assess the relationship between ingredient 
cost, dispensing fees and drug utilization. The significance level for variables was 
0.05. RESULTS: Fee-for-service Medicaid expenditures (n=46 states) reached $27.8 
billion with drug utilization accounting for 173.4 million claims in 2011. Generic 
expenditures represented 17.3% of total expenditures (range=10.3%-29.2%) and 
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generic utilization 72.2% of the claims (range=66.1%-84.8%). The average price of 
generic drug was $17.44 (range=$6.25-$29.12), while the average price of brand 
drugs was $217.07 (range=$105.63-$357.51). The average pharmacy dispensing fee 
was $4.51±$2.03 for generics and $4.26±$2.03 for brands (range for both=$1.75-
$11.50). The ingredient cost was estimated using average wholesaler price (AWP) 
(n=25), wholesaler acquisition cost (WAC, n=11) and combination AWP/WAC 
(n=10). We found no statistical significant relationship between the number of 
claims or the total state expenditures, and the dispensing fee or ingredient cost. 
CONCLUSIONS: Dispensing fees and ingredient cost varied among the different 
states’ Medicaid programs. Those differences were not related to the total 
utilization and expenditures of the state programs. Appropriate reimbursement 
and dispensing fee policies encouraging generic utilization could result in 
substantial saving for the Medicaid program.  
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OBJECTIVES: As the health care safety net continues to grow in both depth and 
breadth, the provider payment system will play an increasing role in the 
resource allocation of health care in China. This paper is intended to assess the 
primary effects of payment reform of capitation experiment and the 
supplementary open enrollment policy in Changde city, China. METHODS: In 
October 2007, Changde employed a capitation approach to pay for health care 
under the Urban Resident Basic Medical Insurance (URBMI), while the fee-for-
service approach was still used by the Urban Employee Basic Medical Insurance 
(UEBMI) in the city and other programs as well. Using the national URBMI 
Household Panel Survey from 2008-2010, we conducted a set of difference-in-
difference (DD) models to assess the capitation policy effect on cost and 
utilization outcomes while controlling for other differences between Changde 
and other cities. RESULTS: The study finds the payment reform to reduce its 
inpatient out-of-pocket cost by 19.7%, out-of-pocket ratio by 9.5%, and length of 
stay by 17.5%. The total inpatient cost, drug cost ratio, treatment effect, and 
patient satisfaction showed little difference between FFS and capitation models. 
The robust tests find the relatively poor health subsample present a similar 
pattern with the results based on the full sample; as for the population cohort 
with good and very good self-rated health conditions, the payment reform in 
Changde has little impact on either providers or patients. CONCLUSIONS: We 
conclude that the payment reform in Changde led to an decrease in the financial 
burden of patients for inpatient care and improve hospital efficiency, without 
compromising quality of care. The total cost measures remain no change 
between capitation and FFS settings, which can be research topics for further 
studies concerning the long term effect of capitation approaches.  
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OBJECTIVES: To investigate treatment patterns of glaucoma and persistence to 
therapy in a large health organization (HMO) in Israel. METHODS: A retrospective 
cohort study, conducted using the electronic medical databases of Maccabi 
Healthcare Services, a 2 million member HMO in Israel. The study population 
consisted of all patients who were newly diagnosed with glaucoma between 2003 
and 2010 at MHS. Collected data included personal characteristics and 
demographics, relevant surgical procedures, prescribed and dispensed anti-
glaucoma medications, and caregiver characteristics. We investigated quality of 
care indices including routine ophthalmologist follow up, performance of 
tonometry tests, as well as persistence to treatment by drug type. Persistence 
was analyzed by proportion of days covered by drugs during follow up time, 
ignoring overlaps due to overuse and simultaneous combination of several types 
of eye drops. RESULTS: A total of 11,512 incident glaucoma patients, who were 
diagnosed between 2003 and 2010 were identified. One quarter of these patients 
remained naïve through the follow-up period, additional 20% were non-adherent 
with therapy (covered less than 20% of the follow up time), and only 13% 
exhibited high persistence (covered at least 80% of the follow-up period). The 
most common physician was ophthalmologist both at treatment initiation (70% 
of initial prescriptions were ophthalmologist vs. 7% by general practitioner) and 
ongoing prescriptions (48% ophthalmologist vs. 22% by general practitioner). 
CONCLUSIONS: The current study demonstrates the potential use of automated 
medical databases to characterize treatment patterns of glaucoma, illustrate the 
great variety of drug therapies, and describe adherence to treatment in the 
community. The increased comorbidity and mortality among these patients has 
important implication for health authorities for prevention and delivery of 
health-care services.  
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OBJECTIVES: To investigate outpatients' knowledge, attitude and awareness 
on medication and analyze the influential factors. METHODS: A total of 711 
outpatients who consented to participate the survey were recruited from 306 
Hospital of PLA in Beijing between 2009-2012. The self-administered question-
naire was composed of XX questions. Multiple linear regressions were run to 
explore the influential factors. Data were analyzed using STATA v11.0. 
RESULTS: The outpatients investigated showed a poor cognition on rational 
drug use. 84.8% of the patients would stop taking drugs by themselves. 60.1% 
of the patients were aware of adverse drug reactions. Age, urban-rural 
difference, knowledge of medication, and health status have different degrees 
of influence on the medication behavior and medication willingness of 
patients, while family income and health insurance have little influence. 
Information provided by the patients was compared with the prescriptions. 
CONCLUSIONS: These results suggest that outpatients in China had much 
misunderstanding about drug use. Patients’ education regarding rational  
drug use is an important issue and deserves urgent improvement. KEY 
WORDS: Outpatients; Cognition; Determin-ants; Rational use of drug; Self-
medication.  
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OBJECTIVES: To determine patient demographics and treatment patterns  
in patients with Crohn’s Disease (CD) who initiated biologic treatment with a 
TNF antagonist (infliximab or adalimumab). METHODS: Patients ≥ 18 years with 
CD (ICD-9:555.X) who initiated a TNF antagonist between January 2007 and  
December 2008 were identified from the US IMPACT health insurance claims 
data-base. Two cohorts were identified; those who received CD related surgery 
(CDSURG) within a 24-month follow-up and those who did not (CDNon-SURG). 
Patients continuously enrolled for medical and pharmacy benefits during 6 
months prior to their first TNF antagonist claim (index claim). RESULTS: A  
total of 812 individuals with CD were followed over a 24-month period, of which 
92% were CDNon-SURG and 8% were CDSURG patients. The majority of patients 
(89%) were 18 to 54 years old with a higher portion of CDSURG patients in the 18-
34 age range. CDSURG included younger patients (mean age: 37 yrs) and a lower 
percent of females (48%) compared to CDNon-SURG (41 yrs; 59% female). 
CDSURG patients had higher hospitalization rates (38%) and incurred more 
health care expenditures ($15,112) during baseline compared to CDNon-SURG 
patients (23%; $13,400). During the last 6 months of follow-up, the percentage of 
CDSURG patients on biologics dropped to 44%; of the 56% in CDSURG who 
discontinued biologics, 31% received no treatment. In contrast, the percentage of 
CDNon-SURG patients continuing biologics decreased to 67% with 37% remaining 
on a “biologic only.” CONCLUSIONS: Most CD patients (92%) initiated on biologics 
did not require surgery, however about one third stopped TNF antagonist 
treatment over 24 months. Although 8% of CD patients underwent surgery, they 
incurred high direct and indirect costs even prior to surgery. Even with 
availability of TNF antagonists, due to high discontinuation rate, there is an 
unmet need of effective CD treatment options that may delay or prevent disease 
progression.  
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OBJECTIVES: To identify patient demographics and treatment use patterns in 
patients with Ulcerative Colitis (UC) who initiated biologic treatment with 
infliximab in a managed care setting. METHODS: Patients with UC (ICD-9 code 
556.X) who initiated infliximab between January 2007 and December 2008 were 
identified from the US IMPACT health insurance claims database. Two cohorts 
were identified based on whether they received UC related surgery (UCSURG) or 
did not receive a UC related surgery (UCNon-SURG) within a 24 month follow-up. 
All patients were continuously enrolled for both medical and pharmacy benefits 
during the 6 months prior to their first infliximab claim (index claim) and 24 
months post index claim. RESULTS: A total of 264 individuals with UC were 
followed over 24-months, of which 84% did not receive surgery (UCNon-SURG) 
and 16% underwent surgery (UCSURG). In both cohorts, mean age was 42 years 
and 45% were women. The majority of patients (80%) were 18 to 54 years old 
with a higher proportion of UCSURG patients in the 35-44 year group range. 
During the 6-month baseline period, UCSURG patients had higher hospitalization 
rates (40%) and incurred more health care expenditures ($17,217) than UCNon-
SURG (22%; $11,774). In the 24 month follow-up, 60% of patients within UCSURG 
underwent surgery during the first year following their index claim. Seventy 
percent of UCNon-SURG patients continued biologics with 34% remaining  
on “biologic only” compared to UCSURG, where 70% had no treatment. 
CONCLUSIONS: Most UC patients (84%) initiated on infliximab did not require 
surgery and continued biologic treatment (70%) over 24 months. Additional 
research is needed to further understand reasons for discontinuation of  
biologic treatment. Although 16% of UC patients underwent surgery, they 
incurred high direct and indirect costs even prior to surgery. There is an unmet 
need of effective UC treatment options that may delay or prevent disease 
progression.  
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